Show simple item record

dc.contributor.authorClifford, Rhonda
dc.contributor.authorBatty, Kevin
dc.contributor.authorDavis, W.
dc.contributor.authorDavis, Timothy
dc.identifier.citationClifford, Rhonda and Batty, Kevin and Davis, Wendy and Davis, Timothy. 2005. Effect of a pharmaceutical care program on vascular risk factors in Type 2 diabetes: the Fremantle diabetes study. Diabetes Care. 28 (4): pp. 771-776.

Objective: To examine the effect of a 12-month pharmaceutical care (PC) program on vascular risk in type 2 diabetes. Research design and methods: We recruited 198 community-based patients randomized to PC or usual care. PC patients had face-to-face goal-directed medication and lifestyle counseling at baseline and at 6 and 12 months plus 6-weekly telephone assessments and provision of other educational material. Clinical, biochemical, and medication-related data were sent regularly to each patient’s physician(s). The main outcome measure was change in HbA1c. A diabetes-specific risk engine was used to estimate changes in 10-year coronary heart disease (CHD) and stroke risk in patients without a history of cardiovascular disease. Conclusions: A 12-month PC program in type 2 diabetes reduced glycemia and blood pressure. Pharmacist involvement contributed to improvement in HbA1c independently of pharmacotherapeutic changes. PC could prove a valuable component of community-based multidisciplinary diabetes care.

dc.publisherAmerican Diabetes Association
dc.titleEffect of a pharmaceutical care program on vascular risk factors in Type 2 diabetes: the Fremantle diabetes study
dc.typeJournal Article
dcterms.source.titleDiabetes Care

Copyright © 2005 by the American Diabetes Association

curtin.accessStatusOpen access via publisher
curtin.facultyFaculty of Health Sciences
curtin.facultySchool of Pharmacy

Files in this item


This item appears in the following Collection(s)

Show simple item record